Keywords: eu, patients, unequal, access, new, drugs, average

EU patients' unequal access to new drugs

Article | 10 June 2002

Print This

On average, UK patients gain access to new medicines six months afterEuropean Union marketing authorization, while in Portugal and France ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in